Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Adjuvant ovarian function suppression in premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2–negative early breast cancer: a multi-center retrospective study

Fig. 3

Disease-free survival difference between underwent OFS or non-OFS among age under 35 women with HR + HER2- breast cancer. (A) Disease-free survival difference between underwent OFS or non-OFS among age under 35 women with HR + HER2- breast cancer before PSM. (B) Disease-free survival difference between underwent OFS or non-OFS among age under 35 women with HR + HER2- breast cancer after 1:1 PSM. PSM, propensity score matching; HR + HER2-, hormone receptor-positive human epidermal growth factor receptor 2-negative; OFS, ovarian function suppression

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us